...
【24h】

Esophagus in-field: a new predictor for esophagitis.

机译:食道野外:食管炎的新预测因子。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To define optimization parameters for limiting esophageal toxicity with concurrent chemoradiation (CRT) for non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: A retrospective analysis of patients treated with concurrent chemoradiation at the Dana-Farber/Brigham and Women's Hospital Cancer Center was done with IRB approval. All patients were treated with concurrent CRT. All patients underwent 3-D conformal radiotherapy planned with ECLIPSE (Varian, Palo Alto, CA) treatment planning system. Patients had their esophagus contoured in two ways: the entire esophagus (Esoph) and esophagus in-field (Esoph(in)). Together with clinical variables, dose volume metrics including mean dose, V5-V60 of both structures (Esoph and Esoph(in)) were analyzed for correlation with acute esophagitis (>/= grade 3) and late esophageal stricture. The analyses and graphics were completed using R (R Development Core Team, 2006). Logistic regression analysis was used to assess the relationships between dosimetric factors and swallowing complications while controlling for non-dosimetric variables. RESULTS: 109 patients were studied between 2000 and 2006. 25% of patients had grade 3 or greater acute esophagitis. 5/109 (5.5%) had late esophageal stricture with a six-month actuarial risk of stricture of 6.5% (95% CI=1-11%). Mean dose and V45-V60 for both Esoph and Esoph(in) significantly correlated with development of acute esophagitis. V55 and V60 for both Esoph and Esoph(in) significantly correlated with development of stricture. On Multivariate analysis V55 of the Esoph and Esoph(in) was most predictive of toxicity. Limiting the V55 Esoph(in) to 50% was the best cut-point for acute esophagitis. CONCLUSIONS: In the setting of concurrent CRT, V55 of the Esoph or Esoph(in) is the best predictor of acute esophagitis.
机译:目的:为限制非小细胞肺癌(NSCLC)同时放化疗(CRT)的食道毒性定义优化参数。材料与方法:在IRB批准下,对Dana-Farber / Brigham和妇女医院癌症中心同时放化疗的患者进行了回顾性分析。所有患者均接受并发CRT治疗。所有患者均接受了采用ECLIPSE(瓦里安,帕洛阿尔托,加利福尼亚)治疗计划系统计划的3-D适形放疗。患者的食道轮廓有两种:整个食道(Esoph)和野外食道(Esoph(in))。连同临床变量一起,分析了包括平均剂量,两种结构的V5-V60(Esoph和Esoph(in))在内的剂量量度指标与急性食管炎(> / = 3级)和晚期食管狭窄的相关性。分析和图形使用R(R Development Core Team,2006)完成。使用逻辑回归分析来评估剂量学因素与吞咽并发症之间的关系,同时控制非剂量学变量。结果:2000年至2006年期间研究了109例患者。其中25%的患者患有3级或以上的急性食管炎。 5/109(5.5%)的患者有食管狭窄,六个月的精算狭窄风险为6.5%(95%CI = 1-11%)。 Esoph和Esoph(in)的平均剂量和V45-V60与急性食管炎的发生密切相关。 Esoph和Esoph(in)的V55和V60与狭窄发展密切相关。在多变量分析中,Esoph和Esoph(in)的V55最能预测毒性。将V55 Esoph(in)限制为50%是急性食管炎的最佳切入点。结论:在同时进行CRT的情况下,Esoph或Esoph(in)的V55是急性食管炎的最佳预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号